Get the full picture
Sign in to uncover key details.
Ventus Therapeutics
Manufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7150 Rue Frederick-Banting Suite 200, Sa...Phone Number
(514) 397-9517Website
www.ventustx.comRevenue
$17.9 MillionIndustry
About Ventus Therapeutics
Ventus Therapeutics specializes in structural immunology to develop therapeutics that target innate immune pathways for various human diseases. Their pipeline includes innovative programs such as VENT-03, a cGAS inhibitor for lupus, and VENT-02, a brain-penetrant NLRP3 inhibitor for Parkinson's disease, both currently in Phase 2 trials. The company aims to address previously undruggable targets and improve treatment options for patients with conditions like IBD and severe asthma. Powered by their ReSOLVE platform, they leverage advances in AI/ML, protein science, and structural biology to enhance drug discovery efficiency.Explore more
Ventus Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Ventus Therapeutics
Compare insights from companies similar to Ventus Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ventus Therapeutics Tech Stack
A closer look at the technologies used by Ventus Therapeutics
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Ventus Therapeutics
Sign Up For FreeTo access detailed company insights
Ventus Therapeutics specializes in structural immunology to develop therapeutics that target innate immune pathways for various human diseases. Their pipeline includes innovative programs such as VENT-03, a cGAS inhibitor for lupus, and VENT-02, a brain-penetrant NLRP3 inhibitor for Parkinson's disease, both currently in Phase 2 trials. The company... Read More
